PLRX logo

PLRXPliant Therapeutics Inc

$1.18
$0.02
(1.72%)
Today
Closed $1.14
$0.04
(3.51%)
After Hours
Updated: 05:03 PM EDT
EarningsAug 6
Mkt Cap$71.83M
Vol491,600.00
News
all
press releases
Atisama Therapeutics Advances RB042 into Multiple Ascending Dose cohorts of Phase 1 Trial and Appoints Bernard Coulie as Chair of the Board
Atisama Therapeutics Advances RB042 into Multiple Ascending Dose cohorts of Phase 1 Trial and Appoints Bernard Coulie as Chair of the Board Atisama Therapeutics Advances RB042 into Multiple Ascending...
PR Newswire
News Placeholder
More News
News Placeholder
Pliant Therapeutics (PLRX) Expected to Announce Quarterly Earnings on Monday
Pliant Therapeutics (NASDAQ:PLRX) will be releasing its Q1 2026 earnings before the market opens on Monday, May 11. (View Earnings Report at...
MarketBeat
News Placeholder
BML Capital Management LLC Buys Shares of 1,546,137 Pliant Therapeutics, Inc. $PLRX
BML Capital Management LLC bought a new stake in Pliant Therapeutics, Inc. (NASDAQ:PLRX - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 1,546,137 shares of the company's stock, valued...
MarketBeat
News Placeholder
Pliant Therapeutics (NASDAQ:PLRX) Upgraded at Wall Street Zen
Wall Street Zen upgraded Pliant Therapeutics from a "sell" rating to a "hold" rating in a research report on Sunday...
MarketBeat
News Placeholder
Wall Street Zen Downgrades Pliant Therapeutics (NASDAQ:PLRX) to Sell
Wall Street Zen downgraded shares of Pliant Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday...
MarketBeat
News Placeholder
Pliant Therapeutics, Inc. (NASDAQ:PLRX) Given Consensus Recommendation of "Reduce" by Analysts
Shares of Pliant Therapeutics, Inc. (NASDAQ:PLRX - Get Free Report) have been assigned an average rating of "Reduce" from the five brokerages that are currently covering the company, Marketbeat.com...
MarketBeat
News Placeholder
Pliant Therapeutics (NASDAQ:PLRX) Shares Up 1.6% - Should You Buy?
Pliant Therapeutics (NASDAQ:PLRX) Trading Up 1.6% - What's Next...
MarketBeat
News Placeholder
Pliant Therapeutics, Inc. (NASDAQ:PLRX) Given Consensus Recommendation of "Reduce" by Brokerages
Shares of Pliant Therapeutics, Inc. (NASDAQ:PLRX - Get Free Report) have earned an average rating of "Reduce" from the five analysts that are currently covering the company, Marketbeat reports. Two research analysts have rated the stock with a sell rating, two have given a hold rating and one has...
MarketBeat
News Placeholder
Canaccord Genuity Group Issues Pessimistic Forecast for Pliant Therapeutics (NASDAQ:PLRX) Stock Price
Canaccord Genuity Group lowered their price target on Pliant Therapeutics from $4.00 to $3.00 and set a "hold" rating for the company in a research note on Friday...
MarketBeat
News Placeholder
Pliant Therapeutics (NASDAQ:PLRX) Issues Quarterly Earnings Results
Pliant Therapeutics (NASDAQ:PLRX - Get Free Report) announced its quarterly earnings data on Wednesday. The company reported ($0.38) earnings per share (EPS) for the quarter, topping the consensus...
MarketBeat
<
1
2
...
>

Advertisement|Remove ads.